Across TCGA pan-cancer cohorts, RNU6-226P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU6-226P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6-226P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-226P is over-expressed in tumor, although a few such as PAAD and ESCA show the opposite, repressed pattern.

KIRC, PAAD, and ESCA are the cancer types where RNU6-226P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-226P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.673	<.001	11	view →
PAAD	Female	All	−0.940	.004	2	view →
ESCA	All	All	−1.177	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNU6-226P RNA expression & survival · all RNU6-226P data types